AFP/Geneva


Human tests of two possible Ebola vaccines have proven safe and now tests to measure their

efficiency will begin within weeks in the three west African countries ravaged by the

deadly virus, the World Health Organisation (WHO) said yesterday.
“These trials are about to begin for the two lead vaccines,” WHO assistant director

general Marie-Paule Kieny told reporters, adding that the vaccines would be tested on tens

of thousands of people across Guinea, Liberia and Sierra Leone.
The Phase III testing to ensure the vaccines actually provide protection against the virus

that has killed 8,259 people in the three African countries is set to begin in Liberia by

the end of the month, she said.
Separate tests are scheduled to start in Sierra Leone and Guinea in February, she added.
There is no licensed treatment or vaccine for Ebola, and the WHO has endorsed rushing

potential ones through trials in a bid to stem the epidemic.
The two potential vaccines that have been undergoing Phase 1 safety tests on humans are

ChAd3, made by Britain’s GlaxoSmithKline, and VSV-EBOV, manufactured by the Public Health

Agency of Canada and developed by Merck.
Tests of the two potential vaccines have been conducted on volunteers in a range of

countries, including Switzerland, Mali, Gabon, Britain, Germany, Canada and the US.
Both have shown to have “an acceptable safety profile,” Kieny said, relaying the findings

of a high-level meeting of policy makers, researchers, regulators and vaccine developers

in Geneva Thursday.
“That is really good news,” she said, acknowledging that “the world is waiting for us to

get these vaccines ready and out to the people with this virus raging through their

communities.”
Millions of doses of the vaccines are expected to be available by the middle of the year,

and tens of millions by 2016, Kieny said.
The three African countries struggling to stop Ebola have chosen radically different

approaches to testing whether the vaccines will actually protect humans against the deadly

virus.
Kieny said Liberia, where the outbreak has proven most fatal so far causing nearly 3,500

deaths, planned to test both vaccines against a third control vaccine, with around 9,000

people receiving each.
Guinea, meanwhile, aimed to test one of the vaccines using a so-called “ring study”

approach that was used to eradicate smallpox, in which the entire village or community

surrounding each infected person is vaccinated.
Kieny said that Guinea planned to offer 4,500 people immediate vaccination and another

4,500 later.
Sierra Leone plans to test one of the vaccines on around 6,000 people, who will receive

their injections in a randomised order.